Abvc Biopharma (ABVC) Non-Current Debt (2014 - 2025)

Abvc Biopharma's (ABVC) quarterly Non-Current Debt came in at $500000.0 in Q3 2025, up 380.0% quarter-over-quarter from $104167.0 in Q3 2021.

Analysis

Abvc Biopharma (ABVC) Non-Current Debt (2014 - 2025) Analysis & Trends

Abvc Biopharma (ABVC) has reported Non-Current Debt for 7 consecutive years, with $500000.0 the latest figure, recorded in Q3 2025.

For the quarter ending Q3 2025, Non-Current Debt changed N/A year-over-year to $500000.0; the trailing twelve-month figure through Sep 2025 stood at $500000.0 (changed N/A YoY), and the FY2020 full-year result was $124400.0, changed N/A from the prior year.
Non-Current Debt grew to $500000.0 in Q3 2025 per ABVC's latest filing, from $104167.0 in the prior quarter.
Across five years, Non-Current Debt topped out at $500000.0 in Q3 2025 and bottomed at $104167.0 in Q3 2021.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Amgen	206.44 Bn	192.45 Bn	7.24 Bn	57.30 Bn
2	Gilead Sciences	179.97 Bn	176.79 Bn	6.22 Bn	26.25 Bn
3	Vertex Pharmaceuticals	130.57 Bn	122.72 Bn	2.84 Bn	-
4	Regeneron Pharmaceuticals	81.63 Bn	73.63 Bn	3.93 Bn	1.99 Bn
5	Argenx Se	60.34 Bn	55.16 Bn	1.37 Bn	-
6	Moderna	54.37 Bn	49.23 Bn	52.00 Mn	591.00 Mn
7	Alnylam Pharmaceuticals	33.07 Bn	29.76 Bn	992.69 Mn	-
8	Biogen	31.84 Bn	30.55 Bn	1.96 Bn	7.29 Bn
9	Roivant Sciences	29.49 Bn	29.49 Bn	1.16 Mn	-
10	Abvc Biopharma	25.56 Mn	25.56 Mn	-	-

Historic Data

Download Data